News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
18
2026
-
05
Renowned financial writer Wu Xiaobo visited Keyuan Pharmaceutical, praising the company’s achievements in digital and intelligent transformation.
Classification：
Corporate News
From May 16 to 17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating intelligent manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with the company’s core management team, and expressed high praise for its practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
Wu Xiaobo and his delegation visited the Keyuan Pharmaceutical API base and the injectable‑AI‑plus‑computing‑power smart factory, conducting on-site inspections of the company’s benchmark digital‑intelligence initiatives. At the API base, the delegation gained an in-depth understanding of the enterprise’s end-to-end intelligent control system, built on industrial Internet and big data technologies. This system enables real-time collection of production data, intelligent monitoring of equipment status, and precise early warning of quality risks, thereby driving simultaneous improvements in both production efficiency and quality‑control standards. Wu Xiaobo commended Keyuan Pharmaceutical for its pioneering efforts to integrate AI across all stages of production management, noting that this approach offers a practical model for the digital transformation of traditional pharmaceutical companies.
At the site of the injectable‑drug smart manufacturing project, Chairman Li Hongfu provided a detailed overview of the core advantages of this major provincial‑level initiative for transforming old and new growth drivers. With a total investment exceeding RMB 500 million and a total floor area of approximately 46,000 square meters, the smart factory seamlessly integrates cutting‑edge technologies such as digital twins, AI‑powered visual inspection, 5G industrial connectivity, and AGV‑based intelligent logistics. It has established two fully automated smart production lines—one for lyophilized powder for injection and one for BFS—and built an end‑to‑end digital‑intelligence management system spanning R&D, production, quality control, and warehousing, thereby setting a new benchmark for high‑end injectable‑drug smart manufacturing.
In recent years, the company has steadily intensified its AI‑driven strategic initiatives, rolled out company‑wide AI‑application training, and advanced the practical deployment of AI across key business functions, including drug discovery, intelligent manufacturing, quality control, and supply chain management. It has also established three state‑of‑the‑art digital‑intelligence production facilities; among them, the oral solid‑dosage‑form plant has earned CMMM Level 3 certification and been recognized as an “Outstanding National Case of Digital Intelligence in the Pharmaceutical and Healthcare Sector,” while the injectable‑drug plant was selected as a “Basic‑Level Smart Factory in Jinan City for 2026.”
Wu Xiaobo highly commended Keyuan Pharmaceutical’s innovative practices in the fields of intelligent manufacturing and digital AI. He noted that the pharmaceutical industry is at a critical juncture in its digital and intelligent transformation, and that Keyuan Pharmaceutical has kept pace with industry trends by leveraging technological innovation to address longstanding challenges in traditional drug production. Its leap—from active pharmaceutical ingredients to finished dosage forms, and from conventional manufacturing to smart, data‑driven production—not only underscores the company’s robust capabilities but also offers valuable, replicable insights for the domestic pharmaceutical sector’s upgrade and transformation. Taking this exchange as an opportunity, the company will further integrate AI technologies across the entire pharmaceutical value chain, steadfastly pursuing three strategic priorities—intelligent manufacturing, digital AI, and green, low‑carbon development—while remaining committed to innovation‑driven growth and digital empowerment, with the aim of becoming a leading benchmark enterprise in the industry’s digital and intelligent transformation.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China